---
title: Dimericon
date: 2024-12-05T13:07:16Z
modified: 2026-08-11T08:36:14Z
permalink: "https://www.htgf.de/en/portfolio/htgffamily/dimericon/"
type: portfolio
status: publish
excerpt: ""
wpid: 118348
language:
  - English
post_translations:
  - pll_6751a58458786
branchen22:
  - Oncology
sectors:
  - Pharmaceuticals
focus_areas:
  - Oncology
timestamp: 2026-08-11T08:36:14Z
tags:
  - English
  - pll_6751a58458786
  - Oncology
  - Pharmaceuticals
---

## Beschreibungstext

Dimericon is a private biotech company focused on exploring the novel modality crosslinked helix dimers (Dimericons) to target hard-to-drug intracellular protein-protein interactions using rationally designed mimetics of helix dimers. The Seed round of financing will support preclinical studies to further develop the current lead compound to be an IND ready clinical candidate in hematological and solid malignancies.

## Adresse

Dimericon Therapeutics AG
Bachtobelstrasse 5
8810 Horgen, Switzerland